Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model - Scorecard - MDSpire

Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model

  • By

  • Liang Zhang

  • Jacqueline Wax

  • Torsten Goldmann

  • Afsaneh Mehrpouyan

  • Antje Müller

  • Frank Petersen

  • Gabriela Riemekasten

  • Xinhua Yu

  • June 5, 2026

  • 0 min

Share

Clinical Scorecard: Tocilizumab Effectively Mitigates Systemic Inflammation in a Humanized Mouse Model, Unlike Siltuximab

At a Glance

CategoryDetail
ConditionSystemic Sclerosis (SSc)
Key Mechanisms
Target Population
Care Setting

Key Highlights

  • Add highlight about immune complex accumulation with Siltuximab.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Measure specific cytokine levels such as IL-6 and anti-nuclear antibodies.

      Risks

        Patient & Prescribing Data

        Include specific efficacy data from the study.

        Clinical Best Practices

        • Add recommendation on patient selection for therapy.

        Related Resources & Content

        Original Source(s)

        Tocilizumab but not Siltuximab prevents systemic inflammation in a humanized mouse model

        • by Liang Zhang, Jacqueline Wax, Torsten Goldmann, Afsaneh Mehrpouyan, Antje Müller, Frank Petersen, Gabriela Riemekasten, Xinhua Yu

        • June 5, 2026

        Related Content

        Case Report: Adult-onset Still’s disease presenting with massive hemorrhagic pericardial effusion without the characteristic rash

        Serum complement system activation in normal healing and atrophic non-union of human long bone fractures

        Editorial: Autoantibodies in cancer: diagnostic, prognostic, and therapeutic potential